Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results, Beats Expectations By $0.51 EPS

Gilead Sciences (NASDAQ:GILD) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.26) by $0.51, Zacks reports. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 EPS.

Gilead Sciences Trading Down 3.0%

Shares of NASDAQ:GILD traded down $4.10 during trading on Wednesday, reaching $131.15. The stock had a trading volume of 3,977,007 shares, compared to its average volume of 7,125,385. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market cap of $162.83 billion, a P/E ratio of 17.87 and a beta of 0.32. The business has a fifty day moving average price of $129.58 and a 200-day moving average price of $136.11. Gilead Sciences has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GILD shares. Morgan Stanley reduced their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Royal Bank Of Canada reduced their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday. Finally, Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $157.93.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, up 10.6% year over year and above the $7.4 billion consensus estimate. Its $6.75 per-share loss was narrower than analysts’ expected loss of approximately $7.07–$7.26. Gilead Q2 Results
• Positive Sentiment: HIV remained the primary growth driver. Product sales excluding Veklury rose 10% to $7.6 billion, while management raised its 2026 HIV growth outlook to 9%–10%. PrEP sales, including the newer Yeztugo product, reportedly doubled to about $1 billion, supporting the possibility of a durable HIV growth engine. Gilead Raises HIV Outlook
• Positive Sentiment: Cantor Fitzgerald reaffirmed its “overweight” rating with a $155 price target, while Needham reaffirmed its “buy” rating and set a $170 target. The recommendations imply meaningful upside from recent trading levels. Analyst Ratings via Benzinga
• Positive Sentiment: The California Supreme Court ruled in Gilead’s favor in a case involving whether drugmakers must develop potentially safer alternatives to existing safe medicines, reducing a notable product-liability risk. California Supreme Court Ruling
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, or $3.28 annualized, yielding approximately 2.4%. The dividend is payable September 29 to shareholders of record September 15.
• Negative Sentiment: Veklury sales fell 81% year over year, prompting Gilead to lower its full-year outlook for the COVID-19 treatment. The company also swung from $2.01 of earnings per share a year earlier to a quarterly loss as acquisition-related costs and R&D spending increased. Veklury and R&D Costs
• Negative Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $1.95 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, and he retained more than 592,000 shares, limiting its significance as a bearish signal.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 82,000 shares of company stock worth $10,641,790 in the last quarter. 0.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the business. Vermillion & White Wealth Management Group LLC boosted its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $31,000. Mcguire Capital Advisors Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $43,000. Finally, Acumen Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $46,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.